MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT - Free Report) from a sell rating to a hold rating in a research report released on Sunday.

Several other equities analysts have also issued reports on MXCT. Stifel Nicolaus reduced their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th.

MaxCyte Price Performance

Shares of NASDAQ:MXCT traded down $0.01 on Friday, hitting $2.30. The company's stock had a trading volume of 738,206 shares, compared to its average volume of 611,114. The company has a 50-day simple moving average of $2.46 and a 200 day simple moving average of $3.41. MaxCyte has a 1 year low of $2.10 and a 1 year high of $5.21. The company has a market capitalization of $244.76 million, a PE ratio of -6.76 and a beta of 1.27.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The company had revenue of $10.39 million for the quarter, compared to analysts' expectations of $9.05 million. On average, equities research analysts expect that MaxCyte will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of MaxCyte

A number of hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new stake in MaxCyte in the first quarter worth about $328,000. Mudita Advisors LLP increased its position in MaxCyte by 3.3% in the first quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock worth $9,087,000 after buying an additional 105,034 shares in the last quarter. AQR Capital Management LLC increased its position in MaxCyte by 227.3% in the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company's stock worth $261,000 after buying an additional 66,323 shares in the last quarter. EntryPoint Capital LLC increased its position in MaxCyte by 190.7% in the first quarter. EntryPoint Capital LLC now owns 129,219 shares of the company's stock worth $353,000 after buying an additional 84,761 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in MaxCyte by 9.8% in the first quarter. Hsbc Holdings PLC now owns 53,556 shares of the company's stock worth $144,000 after buying an additional 4,765 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.